冠状动脉慢性完全闭塞中胶原酶辅助介入治疗研究进展  

Collagenase-assisted interventional therapies for chronic total coronary occlusion

作　　者：申学谦 史雨晨[1] 见闻 柳景华[1] SHEN Xueqian;SHI Yuchen;JIAN Wen;LIU Jinghua(Department of Coronary Heart Disease Center,Beijing Anzhen Hospital,Capital Medical University,Beijing,100029,China)

机构地区：[1]首都医科大学附属北京安贞医院冠心病中心,北京100029

出　　处：《临床心血管病杂志》2022年第12期951-954,共4页Journal of Clinical Cardiology

基　　金：国家自然科学基金(No:81970291、82170344、82200441);国家重点基础研究发展计划(973计划)课题(No:2015CB554404)。

摘　　要：慢性完全闭塞病变(CTO)被称作是冠状动脉经皮介入治疗的最后一座堡垒,基于CTO病变病理成分相关研究而开发的血管内药物辅助介入治疗可软化CTO病变成分,易化导丝通过,目前Ⅱ期临床试验已经完成,有望为CTO病变再通提供新途径。本文就胶原酶辅助介入治疗研究进展进行综述。Chronic total occlusion(CTO)remains one of the major challenging obstacles in coronary intervention.Collagenase-assisted interventional therapy based on the study of pathological components of CTO lesions can soften the components of CTO lesions and make the wire across the lesions easier.PhaseⅡclinical trials have been completed,which is expected to provide a new way for the recanalization of CTO lesions.This article will review the progress in collagenase-assisted interventional therapy.

关 键 词：冠心病 经皮冠状动脉介入治疗 慢性完全闭塞病变 基质金属蛋白酶 

分 类 号：R541.4[医药卫生—心血管疾病]